The Danish statin study included 132,585 people who developed type 2 diabetes in Denmark from 2006 through 2019. All were new statin users or nonusers at diagnosis; anyone who had previously used statins was excluded. The study therefore does not represent everyone with diabetes or dementia. It examined whether the timing of "statin initiation"—starting statin treatment after the diabetes diagnosis—was associated with a later dementia diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Exactly who qualified for the study?
- What treatment strategies did researchers compare?
- What did the study measure and find?
- Does this mean statins prevent dementia?
Exactly who qualified for the study?
The cohort consisted of people recorded as developing type 2 diabetes in Denmark during the study's 2006–2019 entry period. According to The Lancet Regional Health – Europe study, none had used statins before entering the cohort.
That design created a specific population: people with newly diagnosed type 2 diabetes who faced a future decision about starting statins. It did not include previous statin users as a comparison group. The findings should not automatically be applied to:.
- People without type 2 diabetes
- People who had already used statins before their diabetes diagnosis
- Everyone currently living with dementia
- People whose health care circumstances differ substantially from those represented in Denmark's registries
What treatment strategies did researchers compare?
Researchers compared three strategies based on when participants started statins after their type 2 diabetes diagnosis: These categories describe treatment timing, not different statin products or doses. They also do not show why an individual started treatment early, started later, or did not start within five years.
Participants were followed until dementia diagnosis, death, emigration, or December 31, 2021. The observed follow-up therefore extended beyond each person's diabetes diagnosis, but it did not cover an entire lifetime.
- Early initiation: within one year
- Late initiation: more than one year and up to five years later
- No initiation: no statin started within five years
What did the study measure and find?
The primary outcome was the estimated 10-year risk of an all-cause dementia diagnosis. Researchers treated death as a competing risk because dying can prevent dementia from being diagnosed during follow-up. During a median follow-up of 7.1 years, 3,592 participants developed dementia. That was 2.7% of the entire cohort, although the study's main comparisons used estimated 10-year risks.
Early statin initiation was associated with a 3.3% 10-year dementia risk, compared with 3.9% among people who did not start within five years. The published study reported a 15% lower relative risk but a 0.59-percentage-point lower absolute risk. Late initiation was associated with a 3.5% risk. Compared with no initiation within five years, that represented a 10% lower relative risk and a 0.38-percentage-point absolute difference.
Does this mean statins prevent dementia?
No. The study found an association between starting statins and a lower recorded risk of dementia; it did not prove that statins caused the difference. The researchers analyzed observational registry data using target-trial emulation.
This method attempts to structure an observational analysis like a hypothetical clinical trial, but participants were not randomly assigned to the three strategies. The distinction matters because treatment groups can differ in ways that influence their outcomes. The study also measured dementia diagnoses, not changes on cognitive tests or a dedicated dementia-prevention trial endpoint. For a personal treatment decision, readers can ask a clinician: The authors state that randomized trial evidence is still needed to determine whether statin initiation prevents dementia.
- Whether they resemble the study population
- Whether previous statin use makes the comparison inapplicable
- How the small absolute risk differences should be interpreted
- What benefits and concerns matter for their individual situation
